Clinical Trial

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want to know if giving intismeran autogene and pembrolizumab after surgery can help prevent the cancer from coming back in people with non-small cell lung cancer (NSCLC) whose tumors did not respond completely to treatment before surgery (neoadjuvant treatment).
Protocol Amendment History 62 amendments
This ClinicalTrials.gov record has been amended 62 times since 2024-09-30; most recent amendment 2026-07-01.
Status change: Not Yet Recruiting → Recruiting 2024-10-30
Trial Details
NCT Number NCT06623422
Lead Sponsor Merck Sharp & Dohme LLC
Collaborators: ModernaTX, Inc.
Conditions Carcinoma, Non-Small-Cell Lung
Enrollment 680 participants
Start Date 2024-10-21
Primary Completion 2033-05-16 (estimated)
Study Completion 2038-01-26 (estimated)
Updated on ClinicalTrials.gov 2026-08-10